Abstract:Lung cancer is one of the most common malignant tumors and has a poor prognosis and a low survival rate. Traditional treatments, such as radiotherapy and chemotherapy, still face some challenges because of high drug resistance and toxicity. Therefore, it is necessary to discover a new kind of targeted drug with low toxicity and high efficiency. CDK12 is a cell cycle-dependent kinase whose main function is to activate RNA polymerase II (RNAPII) and promote the transcriptional extension of RNA. However, the role and molecular mechanism of CDK12 in lung cancer are still unclear. In this study, the mutation and RNA-Seq data of CDK12 in lung adenocarcinoma and squamous cell carcinoma were downloaded from The Cancer Genome Atlas (TCGA) database and analyzed with the custom scripts. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8) and cell colony formation assays. A subcutaneous tumor experiment in nude mice was used to examine the effects of CDK12 knockdown on the in vivo tumor growth of NSCLC cells. The cell cycle distribution and the apoptosis rate of lung cancer cells were assessed by flow cytometry. Regulation of TANK-binding kinase 1 (TBK1) by CDK12 was evaluated by quantitative PCR, immunoprecipitation and Western blot analysis. In this study we have analyzed the mutation and expression data of The Cancer Genome Atlas (TCGA) database and found that CDK12 is highly expressed in lung cancer tissues. Clinical correlation analysis showed that high expression of CDK12 in NSCLC reduces patient survival, but its high expression is only related to early tumor progression and has no significant correlation with late tumor progression and metastasis. Furthermore, we present evidence that CDK12 depletion in lung cancer cell lines not only leads to the inhibition of cell growth and induces apoptosis but also inhibits tumor growth of NSCLC cells in vivo. CDK12 positively regulates the expression of the oncogene TBK1 in lung cancer cells. These results revealed that CDK12 affects the progression of non-small cell lung cancer through positive regulation of TBK1 expression, suggesting that CDK12 might be a potential molecular target for the treatment of non-small cell lung cancer.

Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.

Lentivirus-Mediated Rna Interference and Over-Expression of Cdk2ap1 Cdna Regulate Cdk2ap1 Expression in Human Lung Cancer A549 Cells

Tpd52l2 Silencing Inhibits Lung Cancer Cell Proliferation By Cell Cycle G2/M Phase Arrest

[Effect of CDK2-AP1 Gene Over-Expression on Proliferation and Cell Cycle Regulation of Breast Cancer Cell Line MCF-7].

PCYT1A Suppresses Proliferation and Migration Via Inhibiting Mtorc1 Pathway in Lung Adenocarcinoma.

STK31 Regulates the Proliferation and Cell Cycle of Lung Cancer Cells Via the Wnt/β‑catenin Pathway and Feedback Regulation by C‑myc.

MiRNA-195-5p Functions As a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Cyclin-dependent Kinase 9 Promotes Cervical Cancer Development Via AKT2/p53 Pathway.

P12(Cdk2-Ap1) Inhibits Breast Cancer Cell Proliferation and in Vivo Tumor Growth

Elevated Expression of CDK4 in Lung Cancer.

Activator Protein-2β Promotes Tumor Growth and Predicts Poor Prognosis in Breast Cancer

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells

CDK10 Suppresses Metastasis of Lung Adenocarcinoma Through Inhibition of the ETS2/c-Raf/p-MEK/p-ERK Signaling Loop

KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway

CDKL1 Promotes Tumor Proliferation and Invasion in Colorectal Cancer

Lentivirus-mediated Knockdown of CTDP1 Inhibits Lung Cancer Cell Growth in Vitro.

Cyclin-dependent Kinase Inhibitor 1A Inhibits Pyroptosis to Enhance Human Lung Adenocarcinoma Cell Radioresistance by Promoting DNA Repair

CKAP2L Promotes Esophageal Squamous Cell Carcinoma Progression and Drug-Resistance by Modulating Cell Cycle

CircKEAP1 Suppresses the Progression of Lung Adenocarcinoma via the miR-141-3p/KEAP1/NRF2 Axis

CDT1, transcriptionally regulated by E2F2, promotes lung adenocarcinoma progression

TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation